Certificate under Regulation 74(5) of the SEBI (D&P) Regulations, 2018 for the quarter ended 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has submitted a routine compliance certificate to BSE for the quarter ended 31st March 2025. The certificate, issued by their Registrar and Transfer Agent Bigshare Services Pvt. Ltd., confirms that all physical share certificates received for dematerialization during the quarter were verified, processed, and the names of depositories were updated in the company's register of members within 15 days, as required under SEBI's Depositories and Participants Regulations. This is a standard quarterly procedural filing with no financial or business details disclosed.
No impact on shareholders or stock price. This is a routine regulatory compliance submission confirming proper handling of share dematerialization requests.